Drugs / LMN-201 Anti-toxin B VHH-2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04893239 | Aug 2021 → Feb 2022 | Clostridium difficile colitis | Lumen Bioscience, Inc. | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LMN-201 Anti-toxin B VHH-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04893239 ↗ |